Timing of Intervention in Mitral Stenosis

Slides:



Advertisements
Similar presentations
Underwriting Impact of New Advances in Valvular Heart Disease NEHOUA 2012 Michael Clark, FACC, FLMI, FBIM Chief Medical Director Swiss Re.
Advertisements

Treatment of Mitral Stenosis.  Medical  Valvotomy  Interventional  Surgical Treatment of Mitral Stenosis.
Mitral Stenosis Emerson Liu Echo conference Nov. 5, 2008.
Timing and indications of surgery in stenotic and regurgitant valvular lesions Dr.Deepak Raju.
Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division under the supervision and administration.
Current Treatment and Future Trends Anthony J. Palazzo, M.D.F.A.C.S.
Echo Conference April 6, 2011 Frances Canet, MD. Causes and Anatomy Assessment of Mitral Stenosis How to Grade Mitral Stenosis Cases and Application Outline.
Mitral valve repair Prof Alain Carpentier is considered the modern day father of MV repair. His publication in the 1980’s called the French correction.
Some Essentials of Valvular Heart Disease CCU lecture series.
Asymptomatic Aortic Stenosis and Exercise Test
Mitral stenosis. Case history #1 A 52-year-old woman presents with gradually increasing dyspnoea on exertion over the past 2 years. Recently she has required.
Case #1 Bicuspid Valve Dilated Aortic Root Mod AI/Mild AS - RW
ECHOCARDIOGRAPHIC EVALUATION OF MITRAL STENOSIS Dr Binjo J Vazhappilly Senior Resident.
How to Do A Mitral Valve Repair for Rheumatic Valve Disease
Valvular Heart Disease: Ambulatory Monitoring and Surgical Referral Dr. Shane Shapera Previous version: Dr. Wassim Saad for AIMGP October 2006.
Mitral Valve Disease Prof JD Marx UFS January 2006.
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,
Valvular Heart Disease Mitral Stenosis
Causes of valve disease Valve regurgitation * Congenital *Acute rheumatic carditis *Chronic rhe. Carditis * I E *Syphlitic aortitis *Dilated Valve.
“For Every Good Idea”
Techniques in Valve-in-Valve TAVR Vinod H. Thourani, MD Professor of Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown Co-Director:
A Contemporary Analysis of Pulmonary Hypertension in Patients Undergoing Mitral Valve Surgery: Is this a Risk Factor? Thank you to the society and panel.
The Impact of Prior Stroke on the Outcome of Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Romain Didier, MD;
Tri-leaflet Aortic Valve. Aortic Stenosis Nishimura, RA et al AHA/ACC Valvular Heart Disease Guideline.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.
Ted Feldman MD, FACC, FESC, FSCAI Disclosure Information The following relationships exist: Grant support: Abbott, BSC, Edwards, St Jude, WL Gore Consultant:
Mitral Stenosis Division of Cardiology, Department of Internal Medicine, College of Medicine, Kyung Hee University R4 Jong Shin Woo.
Incidence and Outcomes of Valve Hemodynamic Deterioration in Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: A Report from the Society.
Location of Thrombus in Non-Rheumatic Atrial Fibrillation SettingNAppendage(%) LA Body (%)Ref. TEE (21%) 1 (0.3%) Stoddard; JACC ’95 TEE233.
Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for the management of patients.
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
Extending the Boundaries of TAVR: Future Directions
Role of Device Therapy in FMR: Challenges and Opportunities
From Mitral Repair to Replacement
Highlights From the SAPIEN 3 Experience in Intermediate-Risk Patients Vinod H. Thourani, MD on behalf of the PARTNER Trial Investigators Professor.
Cardiovascular Research Technologies
Mitral Regurgitation: Epidemiology, Pathophysiology and When to Repair
Cardiothoracic Surgery
Direct Flow Medical Experience with a Conformable, Repositionable, Retrievable, Percutaneous Aortic Valve Reginald Low MD University of California,Davis.
A report from the STS/ACC TVT Registry
Mayra Guerrero, MD, FACC, FSCAI
Is There a Need to Address AF in patients Undergoing Valve Surgery?
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
Direct Flow Medical Experience with a Conformable, Repositionable Retrievable Percutaneous Aortic Valve Reginald Low MD University of California, Davis.
Early Feasibility Studies Investigator Perspective
Figure 1 Representative transoesophageal echocardiographic images of ventricular fibrillation during cardiopulmonary bypass. (A) Mid-oesophageal aortic.
EVEREST II 5-Year Report and Beyond
Department of Cardiology Bern University Hospital
Mohamed Eid Fawzy, FRCP, FACC, FESC October 6 University Cairo, EGYPT
REPRISE I The Sadra Lotus Valve for TVAR
ADULT ECHOCARDIOGRAPHY Lesson Seven The Mitral Valve
James Hermiller, MD, FACC, FSCAI St Vincent Hospital, Indianapolis, IN
University Heart Center Hamburg
Kyle D Buchanan, MD MedStar Washington Hospital Center
MitraClip: A Therapeutic Solution for Patients with Severe MR – Not a Candidate for Surgery Brij Maini MD, FACC Regional Medical Director of Transcatheter.
PREVALENCE EVALUATION AND MANAGEMENT
Cardiovacular Research Technologies
Aortic Valve Treatment in Extensive Ascending Aortic Calcification
Nishith Patel Waikato Cardiothoracic Unit
ADULT ECHOCARDIOGRAPHY Lesson Seven The Mitral Valve
Update in Cardiac and Thoracic Surgery
Benefits of Early Surgery on Clinical Outcomes After Degenerative Mitral Valve Repair  Tianyu Zhou, MD, Jun Li, MD, PhD, Hao Lai, MD, PhD, Kai Zhu, MD,
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Structural Heart Live Cases
Slides courtesy of Dr. Randall Harada
Mitral Stenosis Associated With Valvular Tophi
Rick A. Nishimura et al. JACC 2017;70:
Three mechanisms of early failure of transcatheter aortic valves: Valve thrombosis, cusp rupture, and accelerated calcification  Matthew R. Summers, MD,
Presentation transcript:

Timing of Intervention in Mitral Stenosis Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital CRT Cardiovacular Research Technologies Washington, D.C. February 23 – 26, 2013

Ted E. Feldman, MD Consulting: Abbott Laboratories Boston Scientific Corporation Edwards Lifesciences, LLC

Indications for Percutaneous Mitral Balloon Valvotomy CLASS Indication I A Symptomatic, MVA ≤1.5cm2, MR≤2, no LA clot C Asymptomatic, PASP>50mm Rest/60mm exercise IIa Calcified valve, NYHA III–IV, and are either not candidates or high risk for surgery IIb Asymptomatic with new onset of atrial fibrillation Symptomatic, MVA>1.5 , PASP>60 mmHg, PCW≥25 mm, mn MV gradient >15mm Hg exercise Alternative to surgery with mod-severe MS, calcified valve, NYHA III–IV III Mild MS, moderate to severe MR or left atrial clot JACC 52, 2008:e1–142

Indications for Percutaneous Mitral Balloon Valvotomy CLASS Indication I A Symptomatic, MVA ≤1.5cm2, MR≤2, no LA clot C Asymptomatic, PASP>50mm Rest/60mm exercise IIa Calcified valve, NYHA III–IV, and are either not candidates or high risk for surgery IIb Asymptomatic with new onset of atrial fibrillation Symptomatic, MVA>1.5 , PASP>60 mmHg, PCW≥25 mm, mn MV gradient >15mm Hg exercise Alternative to surgery with mod-severe MS, calcified valve, NYHA III–IV III Mild MS, moderate to severe MR or left atrial clot JACC 52, 2008:e1–142

ECHO Score Mobility Subvalvular Thickening Calcium 1 tips restricted minimal thickening nl (4-5mm) single area 2 mid & base nl 1/3 chordal length leaflet margins 5-8mm scattered 3 valve moves forward thick to distal chords entire leaflet 5-8mm mid leaflets 4 barely mobile extensive to paps >8-10mm thick extensive Br Heart J 60:299,1988

Spectrum of Valve Deformity LA Mild Moderate Severe LV LA LV LA

Left Atrial Smoke

Left Atrial Thrombus Resolution After Warfarin Therapy PRE PRE Post 4 months warfarin 80% of thrombi resolve after 2 months of anticoagulation AHJ 140:150,2000

Organized Left Atrial Thrombus 65F, CABG 6 months prior, Stroke 2 months prior Coumadin 8 for weeks, Successful PTMC

Leaflet Lesion Recent TIA

Mitral Stenosis & Mitral Annular Calcification

Calcific Mitral Stenosis Dialysis

Bioprosthetic Mitral Stenosis 88YO female with atrial fibrillation & bioprosthetic aortic and mitral valve replacement, TV repair in 2009

Bioprosthetic Stenosis 24mm PTMC